viewAnteris Technologies Ltd

Admedus finishes 2015 in strong position after achieving milestones

Lee Rodne, CEO, commented: "In the last 12 months, we have focused on the ongoing global launch of CardioCel and this has resulted in continued quarter on quarter revenue growth and an additional 80 new centres using CardioCel to treat cardiovascular diseases."


Admedus Limited (ASX:AHZ) has finished 2015 in a strong position following a number of key milestones achieved throughout the year.

This includes the HSV-2 therapeutic vaccine Phase II study closing, with initial study results pending; CardioCel® being used in over 135 centres globally; and the Aortic Heart Valve reconstruction study initiated at leading Heart Centres.

Add to this growing revenue and a strong cash position heading into 2016.

Lee Rodne, CEO, commented:

“2015 has been a very positive year for Admedus and we approach 2016 in a very strong position.

"In the last 12 months, we have focused on the ongoing global launch of CardioCel and this has resulted in continued quarter on quarter revenue growth and an additional 80 new centres using CardioCel to treat cardiovascular diseases.

"We have also made significant progress in our immunotherapy programs with key clinical data expected in 2016.”

HSV-2 Study Update

The HSV-2 therapeutic vaccine Phase II study has closed recruitment, with over 40 study participants in the study.

Admedus will continue to progress the existing study participants through the trial to ensure all study participants complete the vaccination period.

The study is progressing well with 25% of study participants having received their six month booster.

The company anticipates the release of additional study data early in the first quarter of 2016 when all study participants have received their initial doses.

HPV Therapeutic Vaccine

Admedus has been working with Professor Ian Frazer on his next HPV product as a treatment against HPV and associated cancers.

In 2015, the HPV therapeutic vaccine continued to show exceptional pre-clinical results targeting HPV and HPV related tumours and is scheduled to enter into a Phase Ib study in 2016 in HPV infected patients.

Aortic Valve Reconstruction Post-market Study

Admedus continues to progress its post market aortic heart valve study with two of the intended four centres now recruiting patients and over 10% of patients already enrolled.

Admedus anticipates the additional study centres to initiate recruitment in the first quarter of 2016.


In the last 12 months, the company achieved approval for CardioCel in Hong Kong, Singapore and Malaysia, opening up more of the Asian market.

In addition, sales of CardioCel have continued to grow with quarter on quarter sales growth throughout 2015, with the December quarter continuing to be strong for sales, a clear indication of growing interest in the product and its benefits for patients.

During the year, an additional 80 centres came on board using CardioCel to treat cardiovascular defects.

The company has also expanded the CardioCel product range with the addition of 2cm X 2cm and 2cm x 8cm sized products.

Admedus will continue to focus on growing revenue for CardioCel in 2016 in both the paediatric and adult markets treating congenital heart defects and repairing and reconstructing heart valves, increasing centre on centre growth and opening up new markets.

Admedus anticipates its first sales in the MENA region in the first quarter of 2016.

Regenerative Tissue Portfolio

Admedus has been very successful this year in expanding the ADAPT® regenerative tissue portfolio for additional soft tissue repair applications.

In 2016, the company is looking to launch a vascular repair tissue product to complement its existing CardioCel sales in the cardiovascular surgical repair and reconstruction market.

The launch of a vascular product franchise will help build company revenue over the coming years and is intended for procedures such as repairing the carotid arteries to reduce the incidence of stroke.

Admedus said that the R&D team will continue to progress key regenerative ADAPT tissue projects in 2016 in dura mater repair (to treat head and brain injuries) as well as progressing the ADAPT tissue scaffolds for stem cell and cellular therapy delivery and ‘off-the shelf’ whole vessels for applications such as coronary artery bypass grafts (CABG).

Admedus will provide updates on these projects throughout 2016.

Rodne added: “2016 is shaping up to be a very exciting and important year for Admedus with growing sales, key product launches, progressing our regenerative tissue pipeline and important clinical milestones in our regenerative tissue and immunotherapy programs.

"The company is looking forward to continuing to build our company with many successes in 2016."


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

Quick facts: Anteris Technologies Ltd

Price: 3.67 AUD

Market: ASX
Market Cap: $21.69 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Anteris Technologies Ltd named herein, including the promotion by the Company of Anteris Technologies Ltd in any Content on the Site, the...


Admedus CEO in New York to update on recent key milestones

Admedus Ltd (ASX:AHZ) CEO Wayne Paterson visited the Proactive Investors New York studio to update on key milestones the company has achieved in the past few months, including receiving European approval on two of its products.

on 03/17/2019

4 min read